智通财经APP讯，诺诚健华(688428.SH)披露2025年第三季度报告，公司前三季度实现营收11.15亿元， 同比增长59.85%;归属于上市公司股东的净利润亏损6441万元;扣非净利润亏损1.35亿元;基本每股收 益-0.04元。 ...

Core Insights - The company, Nuo Cheng Jian Hua (688428.SH), reported a significant revenue increase of 59.85% year-on-year for the first three quarters of 2025, reaching 1.115 billion yuan [1] - Despite the revenue growth, the company recorded a net loss attributable to shareholders of 64.41 million yuan [1] - The revenue growth was primarily driven by the continued sales increase of its core product, Oubutini (Yinokai®), and the recognition of upfront payment income from a licensing agreement with Prolium [1]

Core Viewpoint - The company announced that its newly developed BCL2 inhibitor Mesutoclax and BTK inhibitor Acalabrutinib have over 20 research results selected for the 67th American Society of Hematology (ASH) Annual Meeting, highlighting significant advancements in their clinical research pipeline [1] Group 1: Mesutoclax Research Highlights - Mesutoclax has three studies selected for the ASH meeting, including a presentation on its use in treating Mantle Cell Lymphoma (MCL) and two poster presentations on its application in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Acute Myeloid Leukemia (AML) [1] Group 2: Acalabrutinib Research Highlights - Acalabrutinib has over 20 studies selected for the ASH meeting, featuring one oral presentation and more than 20 poster displays and online releases, covering various disease areas such as Marginal Zone Lymphoma (MZL), Primary Central Nervous System Lymphoma (PCNSL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), and Diffuse Large B-Cell Lymphoma (DLBCL) [1]

Core Viewpoint - The company, Innocare Pharma, will hold an investor briefing on November 14, 2025, to discuss its Q3 2025 financial results and address investor inquiries [2][3][4]. Group 1: Meeting Details - The investor briefing is scheduled for November 14, 2025, from 11:00 AM to 12:00 PM [4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, accessible online [4]. - Investors can participate in the meeting through the internet and submit questions in advance via the Roadshow Center or the company's email [5][6]. Group 2: Participants - Key participants in the meeting will include Dr. Jisong Cui (Chairman and CEO), Ms. Hu Lan (Independent Non-Executive Director), and Mr. Fu Xin (CFO) [4]. - The company may adjust the list of attendees based on special circumstances [4]. Group 3: Investor Interaction - Investors can submit questions from November 7 to November 13, 2025, before 4:00 PM [5]. - The company will respond to commonly asked questions during the briefing [3][5]. Group 4: Contact Information - For inquiries, investors can contact the domestic securities affairs department via phone or email [6]. - The details of the meeting and its main content will be available on the Roadshow Center after the event [6].

Core Insights - The company, Innovent Biologics, announced that its newly developed BCL2 inhibitor Mesutoclax and BTK inhibitor Orelabrutinib have over 20 research results selected for the 67th American Society of Hematology (ASH) Annual Meeting, including 2 oral presentations and 20 poster displays [1][2][4]. Group 1: Mesutoclax Research Highlights - Mesutoclax has three studies selected for the ASH meeting, with one oral presentation focused on its efficacy in treating relapsed/refractory mantle cell lymphoma (MCL) showing high remission rates even in patients previously resistant to BTK inhibitors [1]. - The oral presentation titled "Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients" is scheduled for December 8, 2025 [1]. - Two poster presentations include studies on Mesutoclax's activity in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and myeloid malignancies, demonstrating encouraging efficacy and safety [2][3]. Group 2: Orelabrutinib Research Highlights - Orelabrutinib has over 20 studies selected for the ASH meeting, including one oral presentation and multiple poster displays covering various diseases such as marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL) [4][5]. - The oral presentation titled "Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL" is scheduled for December 6, 2025 [4]. - Key poster presentations include studies on Orelabrutinib combined with other therapies for treating marginal zone lymphoma and DLBCL, indicating promising results [5][6][7]. Group 3: Company Overview - Innovent Biologics is a commercial-stage biopharmaceutical company focused on developing innovative drugs for oncology and autoimmune diseases, with multiple products in commercialization, clinical, and preclinical stages [10]. - The company has branches in major cities including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [10].

Core Points - The company, Innovent Biologics (09969.HK), announced that it will release its Q3 2025 report on November 14, 2025 [1] - To provide investors with a comprehensive understanding of its Q3 2025 operational results and financial status, the company plans to hold a performance briefing on the same day from 11:00 AM to 12:00 PM [1] - The briefing will address questions of interest to investors [1]

Core Viewpoint - The company, Innovent Biologics (09969.HK), announced that it will release its Q3 2025 financial report on November 14, 2025, and will hold a performance briefing to discuss the results and address investor concerns [1] Group 1 - The company plans to hold a performance briefing on November 14, 2025, from 11:00 AM to 12:00 PM [1] - The briefing aims to provide investors with a comprehensive understanding of the company's Q3 2025 operational results and financial status [1] - The event will facilitate communication regarding issues of interest to investors [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 诺诚健华医药有限公司 海外監管公告 本公告乃諾誠健華醫藥有限公司（「本公司」）根據香港聯合交易所有限公司證 券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊登之《關於召開2025年第三季度業績說 明會的公告》。 承董事會命 諾誠健華醫藥有限公司 主席兼執行董事 崔霽松博士 香港，二零二五年十一月五日 於本公告日期，董事會包括主席兼執行董事崔霽松博士；執行董事趙仁濱博士；非執行董事 施一公博士及謝榕剛先生；以及獨立非執行董事胡蘭女士、董丹丹博士及管坤良教授。 | A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2025-037 | | --- | --- | --- | --- | | 港股代码：09969 ...

致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年11月5日 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 | U ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | 本月底法定/註冊股本總額： USD ...